The U.S. Drug Enforcement Administration (DEA) today announced a proposal hearing on the reclassification of marijuana as a less restricted Schedule III drug will happen on Dec. 2, after the presidential election. The news is bringing cannabis stocks back into focus, with Wall Street debating how a Trump or Harris presidency may influence the decision.Canopy Growth Corp (NASDAQ:CGC) stock is among the industry players responding negatively to today's headlines. CGC was last seen down 10.3% at $5.54, and ear ...